Large-Cell Immunoblastic Lymphoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Large-Cell Immunoblastic Lymphoma

What is the definition of Large-Cell Immunoblastic Lymphoma?
A diffuse large B-cell lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, a prominent nucleolus, and abundant cytoplasm.
What are the alternative names for Large-Cell Immunoblastic Lymphoma?
  • Lymphoma, large-cell, immunoblastic
  • Large cell immunoblastic lymphoma
Who are the top Large-Cell Immunoblastic Lymphoma Local Doctors?
Distinguished in Large-Cell Immunoblastic Lymphoma
Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Hematology | Oncology

Ballad Health Cancer Center

2202 North John B. Dennis Highway, Suite 100, 
Kingsport, TN 
Languages Spoken:
English

. Dr. Shipstone is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 54 other conditions, according to our data. His clinical expertise encompasses Adult Immune Thrombocytopenia, Colorectal Cancer, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. Dr. Shipstone is board certified in American Board Of Internal Medicine.

Distinguished in Large-Cell Immunoblastic Lymphoma
Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Hematology | Oncology

Providence Regional Cancer System - Aberdeen

954 Anderson Drive, Suite 102, 
Aberdeen, WA 
Languages Spoken:
English, Japanese
Accepting New Patients
Offers Telehealth

Dr. Sui earned a medical degree from Qingdao University, China, and a Ph.D. from the University of Tokyo, Japan. He conducted postdoctoral research in hematology at Vanderbilt University, an internal medicine residency at the University of Tennessee, and a medical oncology fellowship at the Fred Hutchinson Cancer Research Center and the University of Washington. He is board certified in internal medicine and medical oncology. He was an associate professor at Shangdong. Dr. Sui believes in treating his patients as if they were his own family members. Dr. Sui is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 51 other conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pleuropulmonary Blastoma, and Large-Cell Immunoblastic Lymphoma. Dr. Sui is board certified in American Board Of Internal Medicine. Dr. Sui is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Large-Cell Immunoblastic Lymphoma
Elite in Large-Cell Immunoblastic Lymphoma

Alex Herrera, M.D.

1500 Duarte Rd, 
Duarte, CA 
Experience:
17+ years
Languages Spoken:
English
Offers Telehealth

Alex Herrera is an Oncologist practicing medicine in Duarte, California. He has been practicing medicine for over 17 years. Dr. Herrera is rated as an Elite provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.

What are the latest Large-Cell Immunoblastic Lymphoma Clinical Trials?
MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Summary: This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia or lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). VSV-IFNβ-NIS is a modified vers...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Summary: This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center